Pioglitazone: A boon we know less about
Pioglitazone is a thiazolidinedione that has significant extra-glycemic benefits most promising of which is its anti-atherogenicity. Pioglitazone may be cardioprotective interfering with atherosclerosis at various points such as atherogenesis, plaque inflammation, plaque rupture and hemostatic distu...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
| Series: | Journal of the Scientific Society |
| Subjects: | |
| Online Access: | http://www.jscisociety.com/article.asp?issn=0974-5009;year=2013;volume=40;issue=2;spage=61;epage=63;aulast=Gude |
| id |
doaj-d847cd9db0604412ba3de1bffeaca146 |
|---|---|
| record_format |
Article |
| spelling |
doaj-d847cd9db0604412ba3de1bffeaca1462020-11-24T23:19:45ZengWolters Kluwer Medknow PublicationsJournal of the Scientific Society0974-50092013-01-01402616310.4103/0974-5009.115471Pioglitazone: A boon we know less aboutDilip GudePioglitazone is a thiazolidinedione that has significant extra-glycemic benefits most promising of which is its anti-atherogenicity. Pioglitazone may be cardioprotective interfering with atherosclerosis at various points such as atherogenesis, plaque inflammation, plaque rupture and hemostatic disturbances (i.e., thrombus/embolism formation), and microangiopathy. The far reaching effects of pioglitazone and its extra-glycemic benefits warrant a better place for it in the plethora of drugs that a diabetic is treated with. A review of literature is presented.http://www.jscisociety.com/article.asp?issn=0974-5009;year=2013;volume=40;issue=2;spage=61;epage=63;aulast=GudeAtherosclerosiscardioprotectivepioglitazone |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Dilip Gude |
| spellingShingle |
Dilip Gude Pioglitazone: A boon we know less about Journal of the Scientific Society Atherosclerosis cardioprotective pioglitazone |
| author_facet |
Dilip Gude |
| author_sort |
Dilip Gude |
| title |
Pioglitazone: A boon we know less about |
| title_short |
Pioglitazone: A boon we know less about |
| title_full |
Pioglitazone: A boon we know less about |
| title_fullStr |
Pioglitazone: A boon we know less about |
| title_full_unstemmed |
Pioglitazone: A boon we know less about |
| title_sort |
pioglitazone: a boon we know less about |
| publisher |
Wolters Kluwer Medknow Publications |
| series |
Journal of the Scientific Society |
| issn |
0974-5009 |
| publishDate |
2013-01-01 |
| description |
Pioglitazone is a thiazolidinedione that has significant extra-glycemic benefits most promising of which is its anti-atherogenicity. Pioglitazone may be cardioprotective interfering with atherosclerosis at various points such as atherogenesis, plaque inflammation, plaque rupture and hemostatic disturbances (i.e., thrombus/embolism formation), and microangiopathy. The far reaching effects of pioglitazone and its extra-glycemic benefits warrant a better place for it in the plethora of drugs that a diabetic is treated with. A review of literature is presented. |
| topic |
Atherosclerosis cardioprotective pioglitazone |
| url |
http://www.jscisociety.com/article.asp?issn=0974-5009;year=2013;volume=40;issue=2;spage=61;epage=63;aulast=Gude |
| work_keys_str_mv |
AT dilipgude pioglitazoneaboonweknowlessabout |
| _version_ |
1725577145077465088 |